It has been reported that the use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with G13D-mutated tumors than patients with other KRAS-mutated tumors [20]. Here, KRAS is linked to colorectal cancer.